Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation

Abstract

Background

Women with a BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer. This economic modeling study evaluated different preventive interventions for 30-year-old women with a confirmed BRCA (1 or 2) mutation.

Methods

A Markov model was developed to estimate the costs and benefits [i.e., quality-adjusted life years (QALYs), and life years gained (LYG)] associated with prophylactic bilateral mastectomy (BM), prophylactic bilateral salpingo-oophorectomy (BSO), BM plus BSO, BM plus BSO at age 40, and intensified surveillance. Relevant input data was obtained from a large German database including 5902 women with BRCA 1 or 2, and from the literature. The analysis was performed from the German Statutory Health Insurance (SHI) perspective. In order to assess the robustness of the results, deterministic and probabilistic sensitivity analyses were performed.

Results

With costs of €29,434 and a gain in QALYs of 17.7 (LYG 19.9), BM plus BSO at age 30 was less expensive and more effective than the other strategies, followed by BM plus BSO at age 40. Women who were offered the surveillance strategy had the highest costs at the lowest gain in QALYs/LYS. In the probabilistic sensitivity analysis, the probability of cost-saving was 57% for BM plus BSO. At a WTP of 10,000 € per QALY, the probability of the intervention being cost-effective was 80%.

Conclusions

From the SHI perspective, undergoing BM plus immediate BSO should be recommended to BRCA 1 or 2 mutation carriers due to its favorable comparative cost-effectiveness.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Global Burden of Disease Cancer Collaboration: The global burden of cancer 2013. JAMA Oncol 1(4), 505–527 (2015)

    Article  PubMed Central  Google Scholar 

  2. 2.

    Robert-Koch Institut, Zentrum für Krebsregisterdaten: Brustkrebs (Mammakarzinom). http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html (2015). Accessed 28 Apr2016

  3. 3.

    Rhiem, K., Engel, C., Graeser, M., et al.: The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14(6), R156 (2012). doi:10.1186/bcr3369

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Luengo-Fernandez, R., Leal, J., Gray, A., et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12), 1165–1174 (2013). doi:10.1016/S1470-2045(13)70442-X

    Article  PubMed  Google Scholar 

  5. 5.

    Willems, R.A., Bolman, C.A., Mesters, I., et al.: Cancer survivors in the first year after treatment: the prevalence and correlates of unmet needs in different domains. Psycho-oncology (2015). doi:10.1002/pon.3870

    PubMed  Google Scholar 

  6. 6.

    Sorensen, S.V., Goh, J.W., Pan, F., et al.: Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int. J. Technol. Assess. Health Care 28(1), 12–21 (2012). doi:10.1017/S026646231100064X

    Article  PubMed  Google Scholar 

  7. 7.

    Foster, T.S., Miller, J.D., Boye, M.E., et al.: The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat. Rev. 37(6), 405–415 (2011). doi:10.1016/j.ctrv.2010.12.008

    PubMed  Google Scholar 

  8. 8.

    Cohn, D.E., Kim, K.H., Resnick, K.E., et al.: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29(10), 1247–1251 (2011). doi:10.1200/JCO.2010.32.1075

    Article  PubMed  Google Scholar 

  9. 9.

    Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. National Institute for Health and Clinical Excellence: Guidance. Cardiff (UK) (2013)

  10. 10.

    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0, Aktualisierung 2012, AWMF-Register-Nummer: 032–045OL

  11. 11.

    Nelson, H.D., Pappas, M., Zakher, B., et al.: Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 160(4), 255–266 (2014). doi:10.7326/M13-1684

    Article  PubMed  Google Scholar 

  12. 12.

    Phillips, K.A., Milne, R.L., Rookus, M.A., et al.: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31(25), 3091–3099 (2013). doi:10.1200/JCO.2012.47.8313

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Grann, V.R., Patel, P.R., Jacobson, J.S., et al.: Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res. Treat. 125(3), 837–847 (2011). doi:10.1007/s10549-010-1043-4

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Anderson, K., Jacobson, J.S., Heitjan, D.F., et al.: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann. Intern. Med. 144(6), 397–406 (2006)

    Article  PubMed  Google Scholar 

  15. 15.

    Norum, J., Hagen, A.I., Maehle, L., et al.: Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur. J. Cancer 44(7), 963–971 (2008). doi:10.1016/j.ejca.2008.02.025

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Allgmeine Methoden. Version 4.2 vom 22.04.2015. https://www.iqwig.de/download/IQWiG_Methoden_Version_4-2.pdf (2015). Accessed 28 Apr 2016

  17. 17.

    Schad, M., John, J.: Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur. J. Health Econ 13(2), 127–144 (2012). doi:10.1007/s10198-010-0292-9

    Article  PubMed  Google Scholar 

  18. 18.

    Chen, T., Jansen, L., Gondos, A., et al.: Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur. J. Cancer Prev. 22(1), 59–67 (2013). doi:10.1097/CEJ.0b013e3283552e28

    Article  PubMed  Google Scholar 

  19. 19.

    Holleczek, B., Brenner, H.: Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12, 317 (2012). doi:10.1186/1471-2407-12-317

    Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    German Consortium for Hereditary Breast and Ovarian Cancer. http://www.krebshilfe.de/wir-helfen/adressen/familiaerer-krebs/brustkrebszentren.html (2016). Accessed 28 Apr 2016

  21. 21.

    The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chapter 13: Including non-randomized studies. http://handbook.cochrane.org/chapter_13/13_including_non_randomized_studies.htm (2011). Accessed 31 Jan 2017

  22. 22.

    Land, L.H., Dalton, S.O.: Jensen, et al.: impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res. Treat. 131(3), 1013–1020 (2012). doi:10.1007/s10549-011-1819-1

    Article  PubMed  Google Scholar 

  23. 23.

    Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616–1622 (2002). doi:10.1056/NEJMoa012158

    Article  PubMed  Google Scholar 

  24. 24.

    Domchek, S.M., Friebel, T.M., Singer, C.F., et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967–975 (2010). doi:10.1001/jama.2010.1237

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Mavaddat, N., Peock, S., Frost, D., et al.: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105(11), 812–822 (2013). doi:10.1093/jnci/djt095

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Boughey, J.C., Hoskin, T.L., Degnim, A.C., et al.: Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann. Surg. Oncol. 17(10), 2702–2709 (2010). doi:10.1245/s10434-010-1136-7

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Grann, V.R., Jacobson, J.S., Sundararajan, V., et al.: The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5(5), 283–292 (1999)

    CAS  PubMed  Google Scholar 

  28. 28.

    Grann, V.R., Patel, P., Bharthuar, A., et al.: Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res. Treat. 119(1), 177–184 (2010). doi:10.1007/s10549-009-0373-6

    Article  PubMed  Google Scholar 

  29. 29.

    Peasgood, T., Ward, S.E., Brazier, J.: Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res 10(5), 553–566 (2010). doi:10.1586/erp.10.65

    Article  PubMed  Google Scholar 

  30. 30.

    Havrilesky, L.J., Broadwater, G., Davis, D.M., et al.: Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol. 113(2), 216–220 (2009). doi:10.1016/j.ygyno.2008.12.026

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Ara, R., Wailoo, A.: Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health 15(6), 971–974 (2012). doi:10.1016/j.jval.2012.05.003

    Article  PubMed  Google Scholar 

  32. 32.

    Federal Statistical Office of Germany: Life expectancy 2015. https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html (2015). Accessed 28 Apr 2016

  33. 33.

    Metcalfe, K., Lynch, H.T., Ghadirian, P., et al.: Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 127(1), 287–296 (2011). doi:10.1007/s10549-010-1336-7

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Litiere, S., Werutsky, G., Fentiman, I.S., et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 13(4), 412–419 (2012). doi:10.1016/S1470-2045(12)70042-6

    Article  PubMed  Google Scholar 

  35. 35.

    Winter, W.E., Maxwell, G.L., Tian, C., Gynecologic Oncology Group Study, et al.: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25(24), 3621–3627 (2007)

    Article  PubMed  Google Scholar 

  36. 36.

    Rebbeck, T.R., Friebel, T., Lynch, H.T., et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22(6), 1055–1062 (2004). doi:10.1200/JCO.2004.04.188

    Article  PubMed  Google Scholar 

  37. 37.

    Sullivan, P.W., Lawrence, W.F., Ghushchyan, V.: A national catalog of preference-based scores for chronic conditions in the United States. Med. Care 43(7), 736–749 (2005)

    Article  PubMed  Google Scholar 

  38. 38.

    Dawood, S.: Triple-negative breast cancer: epidemiology and management options. Drugs 70(17), 2247–2258 (2010). doi:10.2165/11538150-000000000-00000

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Holleczek, B., Jansen, L., Brenner, H.: Breast cancer survival in Germany: a population-based high resolution study from Saarland. PLoS One 8(7), e70680 (2013). doi:10.1371/journal.pone.0070680

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Hess, K.R., Esteva, F.J.: Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res. Treat. 137(2), 449–455 (2013). doi:10.1007/s10549-012-2366-0

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Inwald, E.C., Ortmann, O., Zeman, F., et al.: Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed. Res. Int. 2014, 137304 (2014). doi:10.1155/2014/137304

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    DeKoven, M., Bonthapally, V., Jiao, X., et al.: Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 1(5), 453–463 (2012). doi:10.2217/cer.12.43

    Article  PubMed  Google Scholar 

  43. 43.

    Dufresne, A., Pivot, X., Tournigand, C., et al.: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107(2), 275–279 (2008). doi:10.1007/s10549-007-9550-7

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Martin, L.P., Schilder, R.J.: Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol. 36(2), 112–125 (2009). doi:10.1053/j.seminoncol.2008.12.003

    Article  PubMed  Google Scholar 

  45. 45.

    Modesitt, S.C., Jazaeri, A.A.: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin. Pharmacother. 8(14), 2293–2305 (2007). doi:10.1517/14656566.8.14.2293

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Lux, M.P., Reichelt, C., Wallwiener, D., et al.: Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 33(7), 360–368 (2010). doi:10.1159/000315699

    Article  PubMed  Google Scholar 

  47. 47.

    Universitätsklinikum Münster DRG Research Group Medizinisches Management: Webgrouper. http://drg.uni-muenster.de/index.php?option=com_webgrouper&view=webgrouper&Itemid=26 (2015). Accessed 28 Apr 2016

  48. 48.

    Rote Liste® Service GmbH: Rote Liste. http://www.rote-liste.de/ (2015). Accessed 28 Apr 2016

  49. 49.

    Kassenärztliche Bundesvereinigung: Uniform value scale. http://www.kbv.de/html/ebm.php (2015). Accessed 28 Apr 2016

  50. 50.

    Arican, A., Bozkurt, T., Bozcuk, H., et al.: A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support. Care Cancer 22(10), 2629–2634 (2014). doi:10.1007/s00520-014-2253-9

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Verband der Ersatzkassen: Rahmenverträge und Vergütungslisten bei Heilmitteln.. http://www.vdek.com/vertragspartner/heilmittel/rahmenvertrag.html (2015). Accessed 28 Apr 2016

  52. 52.

    IntelliMed GmbH.:Catalog of therapeutic products. http://www.heilmittelkatalog.de/heilmittelkatalog-online.html (2014). Accessed 28 Apr 2016

  53. 53.

    Statistisches Bundesamt. GENESIS-Online Datenbank. https://www-genesis.destatis.de/genesis/online;jsessionid=131E6809880313E767FC8E952532F25D.tomcat_GO_1_3?operation=previous&levelindex=2&levelid=1479294919749&step=2 (2016). Accessed 31 Jan 2017

  54. 54.

    Fryback, D.G., Chinnis Jr., J.O., Ulvila, J.W.: Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int. J. Technol. Assess. Health Care 17(1), 83–97 (2001)

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 18(2 Suppl), S68–S80 (1998)

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Geiger, A.M., Nekhlyudov, L., Herrinton, L.J., et al.: Quality of life after bilateral prophylactic mastectomy. Ann. Surg. Oncol. 14(2), 686–694 (2007). doi:10.1245/s10434-006-9206-6

    Article  PubMed  Google Scholar 

  57. 57.

    Rebbeck, T.R., Mitra, N., Wan, F., et al.: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 1347–1361 (2015). doi:10.1001/jama.2014.5985

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Chai, X., Friebel, T.M., Singer, C.F., et al.: Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 148(2), 397–406 (2014). doi:10.1007/s10549-014-3134-0

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Cappelli, M., Surh, L., Humphreys, L., et al.: Measuring women’s preferences for breast cancer treatments and BRCA1/BRCA2 testing. Qual. Life Res. 10(7), 595–607 (2001)

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Hildebrandt, T., Thiel, F.C., Fasching, P.A., et al.: Health utilities in gynecological oncology and mastology in Germany. Anticancer Res. 34(2), 829–835 (2014)

    PubMed  Google Scholar 

  61. 61.

    Parkin, D., Devlin, N.: Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 15(7), 653–664 (2006). doi:10.1002/hec.1086

    Article  PubMed  Google Scholar 

  62. 62.

    Greiner, W., Claes, C., Busschbach, J.J., von der Schulenburg, J.M.: Validating the EQ-5D with time trade off for the German population. Eur. J. Health Econ. 6(2), 124–130 (2005)

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Chan, Y.M., Ngan, H.Y., Li, B.Y., et al.: A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol. Oncol. 83(1), 10–19 (2001). doi:10.1006/gyno.2001.6345

    CAS  Article  PubMed  Google Scholar 

  64. 64.

    den Heijer, M., Seynaeve, C., Timman, R., et al.: Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur. J. Cancer 48(9), 1263–1268 (2012). doi:10.1016/j.ejca.2011.10.020

    Article  Google Scholar 

  65. 65.

    den Heijer, M., Seynaeve, C., Vanheusden, K., et al.: Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3), 598–604 (2013). doi:10.1002/pon.3039

    Article  Google Scholar 

  66. 66.

    Hooker, G.W., King, L., Vanhusen, L., et al.: Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract 12(1), 9 (2014). doi:10.1186/1897-4287-12-9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dirk Müller.

Additional information

Statement

The analysis was part of the More-Risk Study, an evaluation of the economical, legal, ethical and risk-communicative implications of a risk-adapted screening strategy to detect mamma- and ovarian cancer. The More-Risk Study was funded by the “Federal Ministry of Education and Research” (NKP-332-019).

Authors S. Stock and K. Rhiem are contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 223 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Müller, D., Danner, M., Rhiem, K. et al. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ 19, 341–353 (2018). https://doi.org/10.1007/s10198-017-0887-5

Download citation

Keywords

  • Cost-effectiveness
  • Economic modeling
  • Breast cancer
  • Risk-reducing surgery
  • BRCA